Mechanism of inactivation of enveloped viruses by the biosurfactant surfactin from Bacillus subtilis

Biologicals

Volumn 25, Issue 3, 1997, Pages 289-297

  Vollenbroich, Dirk ^a   Özel, Muhsin ^b   Vater, Joachim ^a   Kamp, Roza Maria ^c   Pauli, Georg ^b  

^a TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

^c BEUTH UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; LIPID; LIPOPEPTIDE; PROTEIN; SURFACTANT; SURFACTIN;

ANIMAL CELL; ANTIBODY TITER; ARTICLE; BACILLUS SUBTILIS; BIOTECHNOLOGY; CALICIVIRUS; CAT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ELECTRON MICROSCOPY; ENCEPHALOMYOCARDITIS VIRUS; FETAL CALF SERUM; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; KINETICS; LIPID BLOOD LEVEL; LIPID MEMBRANE; MOUSE; NONHUMAN; PHARMACEUTICAL ENGINEERING; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEMLIKI FOREST ALPHAVIRUS; SIMIAN IMMUNODEFICIENCY VIRUS; TEMPERATURE; TIME; VESICULAR STOMATITIS VIRUS; VIRUS CAPSID; VIRUS ENVELOPE; VIRUS INACTIVATION;

ALPHAVIRUS; ANIMALIA; BACILLUS SUBTILIS; CALICIVIRIDAE; ENCEPHALOMYOCARDITIS VIRUS; FELIDAE; FELINE CALICIVIRUS; FELIS CATUS; HERPES; HERPESVIRIDAE; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; MIRIDAE; MURINAE; SEMLIKI FOREST VIRUS; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS; SUIDAE; VESICULAR STOMATITIS VIRUS;

EID: 0031234420     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1997.0099     Document Type: Article

References (28)

1. 1. Stephan W. Inactivation of hepatitis viruses and HIV in plasma and plasma derivatives by treatment with β-propiolactone/UV irradiation. In: Morgenthaler J-J (ed.). Virus inactivation in plasma products. Karger Press. 1989; p. 122-127.
2. 2. Horowitz B, Wiebe ME, Lippin A et al. Inactivation of viruses in labile blood derivatives II. Physical methods. Transfusion 1985; 25: 523-527.
3. 3. Horowitz B, Prince AM, Hamman J et al. Viral safety of solvent/detergent-treated blood products. Blood Coagulation Fibrinolysis 1994; 5: S21-S30.
4. 4. Zuber P, Nakano MM, Marahiel MA. Peptide antibiotics. In: Sonenshein AL, Hoch JA, Losick R. (Eds). Bacillus subtilis and other Gram-Positive Bacteria. American Society for Microbiology. 1993; p. 897-919.
5. 5. Karpas A, Lowdell M, Jacobson SK et al. Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506. Proc Natl Acad Sci USA 1992; 89: 8351-8355.
6. 6. Bourinbaiar AS, Lee-Huang S. Comparative in vitro study of contraceptive agents with anti-HIV activity: Gramicidin, nonoxynol-9, and gossypol. Contraception 1994; 49: 131-137.
7. 7. Arima K, Kakinuma A, Tamura G. Surfactin, a crystalline peptidolipid surfactant produced by Bacillus subtilis: Isolation, characterization and its inhibition of fibrin clot formation. Biochem Biophys Res Commun 1968; 31: 488-494.
8. 8. Ishigami Y, Osman M, Nakahara H et al. Significance of β-sheet formation for micellization and surface adsorption of surfactin. Colloids Surfaces B: Biointerfaces 1995; 4: 341-348.
9. 9. Vollenbroich D, Pauli G, Özel M, Vater J. Antimycoplasma properties and application on cell cultures of surfactin, a lipopeptide antibiotic from Bacillus subtilis. Appl Environ Microbiol 1997; 63: 44-49.
10. 10. Bernheimer AW, Avigad LS. Nature and properties of a cytolytic agent produced by Bacillus subtilis. J Gen Microbiol 1970; 61: 361-369.
11. 11. Sheppard JD, Jumarie C, Cooper DG et al. Ionic channels induced by surfactin in planar lipid bilayer membranes. Biochim Biophys Acta 1991; 1064: 13-23.
12. 12. Kameda Y, Ouhira S, Matsui K et al. Anti-tumor activity of Bacillus natto. V. Isolation and characterization of surfactin in the culture medium of Bacillus natto KMD 2311. Chem Pharm Bull 1974; 22: 938-944.
13. 13. Hosono K, Suzuki H. Acylpeptides, the inhibitors of cyclic adenosine 3′,5′-monophosphate phosphodiesterase. III. Inhibition of cyclic AMP phosphodiesterase. J Antibiot Japan 1983; 36: 679-683.
14. 14. Naruse N, Tenmyo O, Kobaru S et al. Pumilacidin, a complex of new antiviral antibiotics: Production, isolation, chemical properties, structure and biological activity. J Antibiot Japan 1990; 43: 267-280.
15. 7] surfactins from Bacillus subtilis. Chem Pharm Bull 1994; 42: 604-607.
16. 16. Baumgart F, Kluge B, Ullrich C, Vater J, Ziessow D. Identification of amino acid substitutions in the lipopeptide surfactin using 2D NMR spectroscopy. Biochem Biophys Res Commun 1991; 177: 998-1005.
17. 17. Kärber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Path Pharmakol 1931; 162: 480.
18. 18. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
19. 19. Gelderblom HR, Hausmann EHS, Özel M et al. Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins. Virology 1987; 156: 171-176.
20. 20. Flick DA, Gifford GE. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods 1984; 68: 167-175.
21. 21. Maget-Dana R, Ptak M. Interactions of surfactin with membrane models. Biophys J 1995; 68: 1937-1943.
22. 22. Tsukagoshi N, Tamura G, Arima K. A novel protoplast-bursting factor (surfactin) obtained from Bacillus subtilis IAM 1213 II. The interaction of surfactin with bacterial membranes and lipids. Biochim Biophys Acta 1970; 196: 211-214.
23. 23. Horowitz B, Piët MPJ, Prince AM et al. Inactivation of lipid-enveloped viruses in labile blood derivatives by unsaturated fatty acids. Vox Sang 1988; 54: 14-20.
24. 24. Kohn A, Gitelman J, Inbar M. Unsaturated free fatty acids inactivate animal enveloped viruses. Arch. Virol. 1980; 66: 301-307.
25. 25. Thormar H, Isaacs CE, Brown HR et al. Inactivation of enveloped viruses and killing of cells by free fatty acids and monoglycerides. Antimicrob Agents Chemother 1987; 31: 27-31.
26. 26. Carrasco L. Entry of animal viruses and macromolecules into cells. FEBS Lett 1994; 350: 151-154.
27. 27. Arima K, Kakinuma A, Tamura G. German patent OS 1,903,987. October 1968.
28. 28. Field AK, Biron KK. "The end of Innocence" revisited: resistance of herpes viruses to antiviral drugs. Clin Microbiol Rev 1994; 7: 1-13.